The generic name of Xenotropic is Progesterone Vaginal Extended-Release Gel, and its use should be done as prescribed by your doctor, and the amount of supplementation should be determined on a case-by-case basis.
Progesterone Vaginal Extended-Release Gel is a vaginal insert that is absorbed through the vaginal epithelial cells and spreads to the uterine body. Application of the drug usually does not require a reduction in dosage, and it is applied at 1 pill per day until after pregnancy, continuing for 10 to 12 weeks.
The drug acts directly on the uterus locally, and the slow release of the drug components allows the local progesterone concentration in the uterus to increase to ensure that the dose is administered locally in the uterus.
It is contraindicated in patients with known hypersensitivity to progesterone or any other component; unexplained vaginal bleeding; hepatic dysfunction or hepatic disease; known or probable mammary or genital malignancy; acute porphyria; thrombophlebitis, thromboembolic disease, or a history of hormone-related thrombophlebitis or thromboembolic disease, cerebral hemorrhage, or a history of associated medical conditions; and induced abortion.
Patients with diabetes mellitus receiving luteal therapy should be closely monitored for blood glucose; the occurrence of unexplained vaginal bleeding should be diagnosed and treated promptly. Because progesterone therapy may cause some degree of fluid retention, the resulting disorders and symptoms (e.g., seizures, migraine headaches, asthma, cardiac or renal insufficiency) should be closely monitored.
The dosage of progesterone vaginal extended-release gel needs to be used under the supervision of a doctor to avoid adverse reactions (e.g., abdominal pain, perineal pain, etc.). Or improper use, resulting in insufficient or excessive supplementation, etc.